Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data

Journal of Biomedical Informatics

Volumn 60, Issue , 2016, Pages 294-308

  Ibrahim, Heba ^a   Saad, Amr ^b,c   Abdo, Amany ^a   Sharaf Eldin, A ^a  

^a HCI LAB   (Egypt)

^b Egyptian Pharmaceutical Vigilance Center (EPVC)   (Egypt)

^c NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

Author keywords

Association rule mining; Drug drug interaction; Logistic regression; Pharmacovigilance; Proportional reporting ratio; RxNorm

Indexed keywords

ALGORITHMS; ASSOCIATION REACTIONS; ASSOCIATION RULES; COMMERCE; DATA MINING; DRUG PRODUCTS; MARKETING; REGRESSION ANALYSIS; SIGNAL DETECTION; SIGNAL PROCESSING;

DRUG-DRUG INTERACTIONS; LOGISTIC REGRESSIONS; PHARMACOVIGILANCE; PROPORTIONAL REPORTING RATIO; RXNORM;

DRUG INTERACTIONS;

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BUDESONIDE PLUS FORMOTEROL; BUPRENORPHINE; CLOPIDOGREL; DIURETIC AGENT; DROSPIRENONE PLUS ETHINYLESTRADIOL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTACAPONE; ESOMEPRAZOLE; FORMOTEROL; HALOTHANE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; ITRACONAZOLE; LEVODOPA; LISINOPRIL; METFORMIN; METFORMIN PLUS SITAGLIPTIN; MIBEFRADIL; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; REMIFENTANIL; SEVOFLURANE; SUXAMETHONIUM; UNINDEXED DRUG; GENERIC DRUG;

ACUTE KIDNEY FAILURE; ADVERSE DRUG REACTION; ALGORITHM; ARTICLE; ASTHMA; DATA COLLECTION METHOD; DATA EXTRACTION; DATA MINING; DRUG FATALITY; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; DYSPHONIA; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART INFARCTION; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INFORMATION PROCESSING; LACTIC ACIDOSIS; LIMB PAIN; LOGISTIC REGRESSION ANALYSIS; PARKINSON DISEASE; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOM SAMPLE; SENSITIVITY AND SPECIFICITY; SIGNAL PROCESSING; SPEECH DISORDER; SPONTANEOUS REPORTING SYSTEMS; STOMACH ULCER; SUICIDAL IDEATION; COMPUTER SYSTEM; FACTUAL DATABASE; PROCEDURES; REGRESSION ANALYSIS; SOFTWARE; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; COMPUTER SYSTEMS; DATA MINING; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DRUGS, GENERIC; HUMANS; PHARMACOVIGILANCE; REGRESSION ANALYSIS; SOFTWARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84959280921     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2016.02.009     Document Type: Article

References (88)

1. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000, 356:1255-1259.
2. Hartford C.G., Petchel K.S., Mickail H., Perez-Gutthann S., McHale M., Grana J.M., Marquez P. Pharmacovigilance during the pre-aPRR oval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf. 2006, 29(8):657-673.
3. Crowther N.R., Holbrook A.M., Kenwright R., Kenwright M. Drug interactions among commonly used medications. Chart simplifies data from critical literature review. Can. Fam. Physician 1997, 43:1972-6-1979-81.
4. Manzi S.F., Shannon M. Drug interactions-a review. Clin. Pediatr. Emergency Med. 2005, 5:93-102.
5. Khouri V., Semnani S.H., Roushandel G.H. Frequency distribution of drug interactions and some of related factors in prescriptions. Med. J. Tabriz Univ. Med. Sci. 2006, 27:29-32.
6. Pirmohamed D., Orrne M.L. Drug interactions of clinical importance. Davies's Textbook of adverse Drug Reactions. London 1998, 888-912. Chapman & Hall Medical, London. D. Davies (Ed.).
7. Van der Heijden P.G., van Puijenbroek E.P., van Buuren S., van der Hofstede J.W. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of underreporting on odds ratios. Stat. Med. 2002, 21(14):2027e44.
8. Olvey E.L., Clauschee S., Malone D.C. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther. 2010, 87(1):48e51.
9. Norén G., Sundberg R., Bate A. A statistical methodology for drug-drug interaction surveillance. Stat. Med. 2008, 27:3057-3070.
10. Rawlins M.D. Spontaneous reporting of adverse drug reactions. II. Uses. Br. J. Clin. Pharmacol. 1988, 26:7-11.
11. Bui Peter H., Quesada Arnulfo, Handforth Adrian, Hankinson Oliver The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. Drug Metab. Dispos. 2008, 36(7):1291-1299.
12. Meinertz T. Mibefradil - a drug which may enhance the propensity for the development of abnormal QT prolongation. Eur. Heart J. 2001, (Suppl. 3):K89-K92.
13. Egyptian Pharmaceutical Vigilance Center (EPVC), 2014. Available from URL: http://epvc.gov.eg.allium.arvixe.com.
14. Diane K., Wysowski L.S. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch. Intern. Med. 2005, 165:1363-1369.
15. U.S. Food and Drug Administration, FAERS quarterly data files; available from URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatory.
16. U.S. Food and Drug Administration (FDA), Guidances of ICH E2B. Available from URL: http://www.fda.gov/RegulatoryInformation/Guidances.
17. P.J. Wiffen, et al. Adverse drug reactions in hospital patients: a systematic review of the prospective and retrospective studies. Bandolier Extra 2002, http://www/jr2.ox.ac.uk/bandolier/extra.html.
18. Ramirez E., Carcas A.J., Borobia A.M., et al. A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients. Clin. Pharmacol. Ther. 2010, 87(1):74-86.
19. Van Puijenbroek E.P., Egberts A.C., Heerdink E.R., Leufkens H.G. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. 2000, 56(9-10):733-738.
20. Van Puijenbroek E.P., Egberts A.C., Meyboom R.H., Leufkens H.G. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br. J. Clin. Pharmacol. 1999, 47(6):689-693.
21. Norén G.N., Sundberg R., Bate A., Edwards I.R. A statistical methodology for drug-drug interaction surveillance. Stat. Med. 2008, 27(16):3057-3070.
22. Thakrar B.T., Grundschober S.B., Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br. J. Clin. Pharmacol. 2007, 64(4):489-495.
23. Harpaz R., Haerian K., Chase H.S., Friedman C. Statistical mining of potential drug interaction adverse effects in FDA's spontaneous reporting system. Proc. AMIA Annu. Symp. 2010, 281-285.
24. Tatonetti N.P., Fernald G.H., Altman R.B. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J. Am. Med. Inform. Assoc. 2012, 19(1):79-85.
25. Iyer S.V., Harpaz R., LePendu P., Bauer-Mehren A., Shah N.H. Mining clinical text for signals of adverse drug-drug interactions. J. Am. Med. Inform. Assoc. 2014, 21(2):353-362.
26. C.C. Yang, L. Jiang, H. Yang, X. Tang, Detecting Signals of Adverse Drug Reactions from Health Consumer Contributed Content in Social Media, in: Proceedings of ACM SIGKDD Workshop on Health Informatics, Beijing, August 12, 2012.
27. C.C. Yang, H. Yang, L. Jiang, M. Zhang, Social media mining for drug safety signal detection, in: Proceedings of ACM CIKM International Workshop on Smart Health and Wellbeing, Maui, Hawaii, 2012, pp. 33-40.
28. Yang C.C., Yang H., Jiang L. Postmarketing drug safety surveillance using publicly available health consumer contributed content in social media. ACM Transact. Manage. Inform. Syst. (TMIS) 2014, 5(1):2-21.
29. H. Yang, C.C. Yang, Harnessing social media for drug-drug interactions detection, in: Proceedings of IEEE International Conference on Healthcare Informatics, Philadelphia, PA, 2013, pp. 22-29.
30. Hauben M., Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov. Today 2009, 14(7-8):343-357.
31. Medical Dictionary for Regularity Activities (MedDRA), Available from URL: http://www.meddramsso.com.
32. International Conference on Harmonisation, ICH E2b template, Available from URL (last accessed 2015 March). http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
33. McCray A.T., Aronson A.R., Browne A.C., Rindflesch T.C., Razi A., Srinivasan S. UMLS knowledge for biomedical language processing. Bull. Med. Libr. Assoc. 1993, 81(2):184-194.
34. Stuart J.N., Kelly Z., John K., Tammy P., Robin M. Normalized names for clinical drugs: RxNorm at 6 years. J. Am. Med. Inform. Assoc. 2011, 18(4):441-448.
35. U.S. National Library of Medicine, UMLS® Reference Manual, Available from URL: http://www.ncbi.nlm.nih.gov/books/NBK9685/.
36. Drugs.com website, Drugs.com Interactions Checker, Available from URL: http://www.drugs.com/drug_interactions.php.
37. DrugBank website, Available from URL: http://www.drugbank.ca/.
38. I. Segura-Bedmar, P. Martinez, C. De Pablo-Sánchez, Combining syntactic information and domain-specific lexical patterns to extract drug-drug interactions from biomedical texts, in: Proceedings of the ACM Fourth International Workshop on Data and Text Mining in Biomedical Informatics (DTMBIO'10), 2010, pp. 49-56.
39. Epocrates RX, Available from URL: http://www.epocrates.com/products.
40. Physician Desk Reference (PDR), Available from URL: http://www.pdr.net/browse-by-drug-name.
41. Medicines Complete website, Available from URL: https://www.medicinescomplete.com.
42. e-Therapeutics, Available from URL: http://www.e-therapeutics.ca/.
43. Medscape, Available from URL: http://reference.medscape.com/.
44. U.S. Food and Drug Administration (FDA), Drugs@FDA, Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
45. A.L. Matthew, K. Marina, M.D. Ankur, L.R. David, Extraction and Mapping of Drug Names from Free Text to a Standardized Nomenclature. AMIA Annu. Symp. Proc. 2007, 2007, pp. 438-442.
46. R. Agrawal, T. Imielinski, A. Swami, Mining association rules between sets of items in large databases, in: Proceedings of the ACM SIGMOD International Conference on Management of Data, 1993, pp. 207-216.
47. Sarawagi S., Thomas S., Agrawal R. Integrating association rule mining with relational database systems: alternatives and implications. Data Min. Knowledge Discov. 2000, 4(2):89-125.
48. L. Dingcheng, S. Gyorgy, G.C. Christopher, P. Jyotishman, Using Association Rule Mining for Phenotype Extraction from Electronic Health Records. AMIA Jt. Summits Transl. Sci. Proc. 2013, 2013, pp. 142-146.
49. Stephen E.B., Alan P.S., Michael H., Ken B., Warren T.J., Stephen A.M. Association rules and data mining in hospital infection control and public health surveillance. J. Am. Med. Inform. Assoc. 1998, 5(4):373-381.
50. Kuo M.H., Kushniruk A.W., Borycki E.M., Greig D. Application of the Apriori algorithm for adverse drug reaction detection. Stud. Health Technol. Inform. 2009, 148:95-101.
51. R. Srikant, Q. Vu, R. Agrawal, Mining Association Rules with Item Constraints, in: Proceedings of the KDD 97, 1997, pp. 67-73.
52. Evans S.J.V., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 2001, 10:483-486.
53. Parikh R., Mathai A., Parikh S., Sekhar G.C., Thomas R. Understanding and using sensitivity, specificity and predictive values. Indian J. Ophthalmol. 2008, 56(1):45-50.
54. Stein P.D., Hull R.D., Patel K.C., et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann. Intern. Med. 2004, 140(8):589-602.
55. H. Yang, C.C. Yang, Drug-drug interactions detection from online heterogeneous healthcare network, in: Proceedings of IEEE International Conference on Healthcare Informatics (ICHI), VR, Italy, 2014, pp. 7-16.
56. Harpaz R., DuMouchel W., LePendu P., Bauer-Mehren A., Ryan P., Shah N.H. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 2013, 93(6):539-546.
57. Jager K.J., Zoccali C., Macleod A., Dekker F.W. Confounding: what is it and how do we deal with it?. Kidney Int. 2008, 73(3):256-260.
58. Noren G.N., Bate A., Orre R., Edwards I.R. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat. Med. 2006, 25(21):3740-3757.
59. Hopstadius J., Norén G.N., Bate A., Edwards I.R. Impact of stratification on adverse drug reaction surveillance. Drug Saf. 2008, 31(11):1035-1048.
60. Jewell Nicholas P. Statistics for Epidemiology. Texts for Statistical Sciences 2004, Chapman and Hall. Hardcover ed.
61. Schillevoort I., van Puijenbroek E.P., de Boer A., Roos R.A., Jansen P.A., Leufkens H.G. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int. Clin. Psychopharmacol. 2002, 17(2):75-79.
62. Lalau J.D. Lactic acidosis induced by metformin. Drug Saf. 2010, 33(9):727-740.
63. Esomeprazole APRR OVAL FDA LABEL, Drugs@FDA, 2001, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.
64. Formoterol APRR OVAL FDA LABEL, Drugs@FDA, 2001, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012.
65. Aaronson D.W. The "black box" warning and allergy drugs. J. Allergy Clin. Immunol. 2006, 117(1):40-44.
66. Alisa K., Anita K., Elmir J., Zijah R., Goran K. Influence of remifentanil/propofol anesthesia on ventilator-associated pneumonia occurrence after major cardiac surgery. Med Arch 2013, 67(6):407-409.
67. Entacapone APRR OVAL FDA LABEL, Drugs@FDA, 1999, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.
68. Plavix APRR OVAL LABEL, Drugs@FDA, 1997, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013.
69. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22(2):414-423.
70. Menon S.P., Rajkumar S.V., Lacy M., Falco P., Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008, 112(7):1522-1528.
71. Shahabudin S., Bharti C., Faizal P. Surveillance of the potential drug-drug interactions in the medicine department of a tertiary care hospital. J. Clin. Diagn. Res. 2012, 6(7):1258-1261.
72. YAZ APRR OVAL LABEL, Drugs@FDA, 2006, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.
73. Mycophenolate APRR OVAL LABEL, Drugs@FDA, 1995, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013.
74. Tacrolimus APRR OVAL LABEL, Drugs@FDA, 2009, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009.
75. Claeys L.G., Berg W. Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy. Eur. J. Vasc. Endovasc. Surg. 2003, 25(1):85-87.
76. Abciximab APRR OVAL LABEL, Drugs@FDA, 1993, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013.
77. Symbicort®APRR OVAL LABEL, 2006, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010.
78. Abacavir APRR OVAL LABEL, Drugs@FDA, 1998, Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.
79. Ritonavir APRR OVAL LABEL, Drugs@FDA, 1996, Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.
80. Andersen D.K., et al. PANCREATITIS - DIABETES - PANCREATIC CANCER: summary of an NIDDK-NCI workshop. Pancreas 2013, 42(8):10.
81. Suboxone APRR OVAL LABEL, Drugs@FDA, 2002, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014.
82. Rosuvastatin APRR OVAL LABEL, Drugs@FDA, 2003, Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label.
83. Metformin APRR OVAL LABEL, Drugs@FDA, 2002, Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014.
84. Vilar S., Harpaz R., Chase H.S., et al. Facilitating adverse drug event detection pharmacovigilance databases using molecular structure similarity: application rhabdomyolysis. J. Am. Med. Inform. Assoc. 2011, 18(Suppl. 1). i73-e80.
85. Wishart D.S., et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucl. Acids Res. 2008, 36(Database issue):D901-D906.
86. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31(7):815-832.
87. Greene N., Judsona P.N., Langowskia J.J., Marchanta C.A. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR & QSAR. Environ. Res. 1999, 10(2-3):299-313.
88. Gomba V.K., Enslein K., Blake B.W. Assessment of developmental toxicity potential of chemicals by quantitative structure-toxicity relationship models. Chemosphere 1995, 31(1):2499-2510.